Bringing hope with life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our lead program, QLS-215, is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of Hereditary Angioedema (HAE)
January 29, 2021: Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
November 12, 2020: Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
October 26, 2020: Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
Join Our Team